Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
The Oncologist · 08.05.2023 · 28 (5) · 433-439
DOI: 10.1093/oncolo/oyac262 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 14.01.2023. Verfasst von Omar Alhalabi und 15 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
There remains a paucity of data regarding the efficacy of immune checkpoint therapy (ICT) combinations ± vascular endothelial growth factor (VEGF) targeted therapy (TT) in translocation renal cell carcinoma (tRCC).
Methods
This is a retrospective study of patients with advanced tRCC treated with ICT combinations at 11 centers in the US, France, and Belgium. Only cases with confirmed fluorescence in situ hybridization (FISH) were included. Objective response rates (ORR) and progression-free survival (PFS) were assessed by RECIST, and overall survival (OS) was estimated by Kaplan-Meier methods.
Results
There were 29 patients identified with median age of 38 (21-70) years, and F:M ratio 0.9:1. FISH revealed TFE3 and TFEB translocations in 22 and 7 patients, respectively. Dual ICT and ICT + VEGF TT were used in 18 and 11 patients, respectively. Seventeen (59%) patients received ICT combinations as first-line therapy. ORR was 1/18 (5.5%) for dual ICT and 4/11 (36%) for ICT + VEGF TT. At a median follow-up of 12.9 months, median PFS was 2.8 and 5.4 months in the dual ICT and ICT + VEGF TT groups, respectively. Median OS from metastatic disease was 17.8 and 30.7 months in the dual ICT and ICT + VEGF TT groups, respectively.
Conclusion
In this retrospective study of advanced tRCC, limited response and survival were seen after frontline dual ICT combination therapy, while ICT + VEGF TT therapy offered some efficacy. Due to the heterogeneity of tRCC, insights into the biological underpinnings are necessary to develop more effective therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
- Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France.
- Institut de Cancérologie Strasbourg Europe (ICANS/HUS), Strasbourg, France.
- Université Lyon I, Centre Léon Bérard, Lyon, France.
- Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre-Université de Paris, Paris, France.
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
ORCID-Profile: Omar Alhalabi, Jonathan Thouvenin, Yann-Alexandre Vano, Luca Campedel, Ziad Bakouny, Pavlos Msaouel, Toni K Choueiri, Srinivas R Viswanathan, Kanishka Sircar, Laurence Albiges
Zitieren
APA
Alhalabi, O., Thouvenin, J., Négrier, S., Vano, Y. A., Campedel, L., Hasanov, E., Bakouny, Z., Hahn, A. W., Bilen, M. A., Msaouel, P., Choueiri, T. K., Viswanathan, S. R., Sircar, K., Albiges, L., Malouf, G. G., & Tannir, N. M. (2023). Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. The Oncologist, 28(5), 433-439. https://doi.org/10.1093/oncolo/oyac262
Vancouver
Alhalabi O, Thouvenin J, Négrier S, Vano YA, Campedel L, Hasanov E, et al. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. The Oncologist. 2023;28(5):433-439. doi:10.1093/oncolo/oyac262
BibTeX
@article{Alhalabi2023,
author = {Alhalabi, Omar and Thouvenin, Jonathan and Négrier, Sylvie and Vano, Yann-Alexandre and Campedel, Luca and Hasanov, Elshad and Bakouny, Ziad and Hahn, Andrew W and Bilen, Mehmet Asim and Msaouel, Pavlos and Choueiri, Toni K and Viswanathan, Srinivas R and Sircar, Kanishka and Albiges, Laurence and Malouf, Gabriel G and Tannir, Nizar M},
title = {Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {5},
pages = {433--439},
doi = {10.1093/oncolo/oyac262}
}
EUVIMED